| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
8,137 |
7,682 |
$639K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
8,812 |
8,300 |
$482K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
386 |
378 |
$44K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
272 |
271 |
$24K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
147 |
147 |
$17K |
| 80306 |
|
1,489 |
1,472 |
$8K |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
44 |
44 |
$7K |
| 64493 |
|
24 |
24 |
$5K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
3,722 |
3,476 |
$5K |
| 64495 |
|
24 |
24 |
$3K |
| 64494 |
|
24 |
24 |
$3K |
| 99401 |
|
140 |
139 |
$3K |
| 99442 |
|
32 |
32 |
$2K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
22 |
21 |
$634.92 |
| 86769 |
|
14 |
14 |
$435.82 |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
417 |
400 |
$200.15 |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
199 |
184 |
$129.06 |
| 81025 |
|
24 |
24 |
$86.35 |
| G8427 |
Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications |
7,672 |
7,237 |
$67.78 |
| 36415 |
Collection of venous blood by venipuncture |
17 |
17 |
$4.86 |
| G8417 |
Bmi is documented above normal parameters and a follow-up plan is documented |
5,587 |
5,290 |
$4.84 |
| G9903 |
Patient screened for tobacco use and identified as a tobacco non-user |
4,733 |
4,480 |
$0.01 |
| G9906 |
Patient identified as a tobacco user received tobacco cessation intervention during the measurement period or in the six months prior to the measurement period (counseling and/or pharmacotherapy) |
1,279 |
1,222 |
$0.01 |
| G9902 |
Patient screened for tobacco use and identified as a tobacco user |
1,033 |
988 |
$0.01 |
| 1036F |
|
2,444 |
2,318 |
$0.00 |